Masimo (MASI) Competitors

$178.31 -0.19 (-0.11%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$178.28 -0.03 (-0.02%)

As of 05/8/2026 05:40 PM Eastern

MASI vs. AMN, VEEV, RMD, DXCM, and STE

Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include AMN Healthcare Services (AMN), Veeva Systems (VEEV), ResMed (RMD), DexCom (DXCM), and STERIS (STE). These companies are all part of the "medical" sector.

How does Masimo compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, AMN Healthcare Services and AMN Healthcare Services both had 10 articles in the media. AMN Healthcare Services' average media sentiment score of 0.75 beat Masimo's score of 0.71 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Masimo	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 9.7% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AMN Healthcare Services has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.41	-$95.70M	-$2.49	N/A
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A

AMN Healthcare Services has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Masimo has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

AMN Healthcare Services presently has a consensus target price of $22.93, indicating a potential downside of 20.53%. Masimo has a consensus target price of $180.40, indicating a potential upside of 1.17%. Given Masimo's higher possible upside, analysts clearly believe Masimo is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Masimo has a net margin of 4.90% compared to AMN Healthcare Services' net margin of -0.95%. Masimo's return on equity of 31.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.59%	5.46%
Masimo	4.90%	31.33%	13.93%

Summary

AMN Healthcare Services and Masimo tied by winning 8 of the 16 factors compared between the two stocks.

How does Masimo compare to Veeva Systems?

Masimo (NASDAQ:MASI) and Veeva Systems (NYSE:VEEV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

86.0% of Masimo shares are owned by institutional investors. Comparatively, 88.2% of Veeva Systems shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 10.3% of Veeva Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Veeva Systems has a net margin of 28.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Veeva Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
Veeva Systems	28.44%	13.80%	11.39%

Masimo presently has a consensus target price of $180.40, indicating a potential upside of 1.17%. Veeva Systems has a consensus target price of $278.70, indicating a potential upside of 67.68%. Given Veeva Systems' stronger consensus rating and higher probable upside, analysts plainly believe Veeva Systems is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veeva Systems	1 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.65

Masimo has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Veeva Systems has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

In the previous week, Veeva Systems had 16 more articles in the media than Masimo. MarketBeat recorded 26 mentions for Veeva Systems and 10 mentions for Masimo. Masimo's average media sentiment score of 0.71 beat Veeva Systems' score of 0.71 indicating that Masimo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Veeva Systems	12 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Veeva Systems has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
Veeva Systems	$3.20B	8.50	$908.91M	$5.41	30.72

Summary

Veeva Systems beats Masimo on 13 of the 17 factors compared between the two stocks.

How does Masimo compare to ResMed?

Masimo (NASDAQ:MASI) and ResMed (NYSE:RMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
ResMed	$5.15B	5.85	$1.40B	$10.37	19.93

ResMed has a net margin of 27.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
ResMed	27.44%	25.35%	18.69%

Masimo has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Masimo presently has a consensus target price of $180.40, indicating a potential upside of 1.17%. ResMed has a consensus target price of $286.18, indicating a potential upside of 38.49%. Given ResMed's stronger consensus rating and higher probable upside, analysts plainly believe ResMed is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

86.0% of Masimo shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 9.7% of Masimo shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ResMed had 8 more articles in the media than Masimo. MarketBeat recorded 18 mentions for ResMed and 10 mentions for Masimo. ResMed's average media sentiment score of 0.99 beat Masimo's score of 0.71 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Masimo on 12 of the 17 factors compared between the two stocks.

How does Masimo compare to DexCom?

Masimo (NASDAQ:MASI) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
DexCom	$4.66B	5.02	$836.30M	$2.34	25.90

DexCom has a net margin of 19.31% compared to Masimo's net margin of 4.90%. DexCom's return on equity of 33.33% beat Masimo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
DexCom	19.31%	33.33%	13.19%

Masimo has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, DexCom has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Masimo presently has a consensus target price of $180.40, suggesting a potential upside of 1.17%. DexCom has a consensus target price of $83.50, suggesting a potential upside of 37.77%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88

86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, DexCom had 13 more articles in the media than Masimo. MarketBeat recorded 23 mentions for DexCom and 10 mentions for Masimo. DexCom's average media sentiment score of 1.18 beat Masimo's score of 0.71 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	16 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Masimo on 14 of the 17 factors compared between the two stocks.

How does Masimo compare to STERIS?

Masimo (NASDAQ:MASI) and STERIS (NYSE:STE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

In the previous week, STERIS had 5 more articles in the media than Masimo. MarketBeat recorded 15 mentions for STERIS and 10 mentions for Masimo. STERIS's average media sentiment score of 0.89 beat Masimo's score of 0.71 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Masimo presently has a consensus target price of $180.40, suggesting a potential upside of 1.17%. STERIS has a consensus target price of $275.20, suggesting a potential upside of 32.69%. Given STERIS's stronger consensus rating and higher possible upside, analysts plainly believe STERIS is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

86.0% of Masimo shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

STERIS has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.12	-$151.50M	-$10.54	N/A
STERIS	$5.46B	3.73	$614.64M	$7.17	28.93

Masimo has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

STERIS has a net margin of 12.15% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
STERIS	12.15%	14.34%	9.58%

Summary

STERIS beats Masimo on 11 of the 16 factors compared between the two stocks.

Get Masimo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASI vs. The Competition

Export

Metric	Masimo	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.35B	$7.16B	$6.25B	$12.12B
Dividend Yield	N/A	1.71%	2.78%	5.20%
P/E Ratio	-16.92	49.10	20.64	25.39
Price / Sales	6.12	56.50	534.02	75.96
Price / Cash	38.43	24.93	43.29	53.47
Price / Book	11.84	5.81	9.98	6.81
Net Income	-$151.50M	$158.34M	$3.54B	$333.04M
7 Day Performance	-0.10%	-0.39%	3.50%	3.15%
1 Month Performance	-0.01%	4.88%	4.17%	7.12%
1 Year Performance	13.44%	-0.25%	41.85%	41.21%

Masimo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASI Masimo	1.4053 of 5 stars	$178.31 -0.1%	$180.40 +1.2%	N/A	$9.35B	$1.53B	N/A	2,200	Analyst Upgrade
AMN AMN Healthcare Services	1.877 of 5 stars	$21.00 +3.2%	$22.64 +7.8%	N/A	$786.35M	$2.73B	N/A	2,664	Trending News Earnings Report Analyst Forecast Gap Up
VEEV Veeva Systems	4.8046 of 5 stars	$160.43 -0.4%	$278.70 +73.7%	N/A	$26.32B	$3.20B	29.65	7,928
RMD ResMed	4.8707 of 5 stars	$222.11 +1.0%	$294.55 +32.6%	N/A	$32.03B	$5.15B	21.97	10,600
DXCM DexCom	4.5615 of 5 stars	$61.41 -0.3%	$86.50 +40.9%	N/A	$23.76B	$4.66B	29.24	11,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASI) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, RMD, DXCM, and STE

How does Masimo compare to AMN Healthcare Services?

Summary

How does Masimo compare to Veeva Systems?

Summary

How does Masimo compare to ResMed?

Summary

How does Masimo compare to DexCom?

Summary

How does Masimo compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, RMD, DXCM, and STE

How does Masimo compare to AMN Healthcare Services?

Does the media prefer AMN or MASI?

Do institutionals and insiders have more ownership in AMN or MASI?

Which has preferable valuation & earnings, AMN or MASI?

Which has more volatility and risk, AMN or MASI?

Do analysts recommend AMN or MASI?

Is AMN or MASI more profitable?

Summary

How does Masimo compare to Veeva Systems?

Do institutionals & insiders have more ownership in MASI or VEEV?

Is MASI or VEEV more profitable?

Do analysts prefer MASI or VEEV?

Which has more risk & volatility, MASI or VEEV?

Does the media favor MASI or VEEV?

Which has stronger earnings and valuation, MASI or VEEV?

Summary

How does Masimo compare to ResMed?

Which has stronger earnings and valuation, MASI or RMD?

Is MASI or RMD more profitable?

Which has more risk & volatility, MASI or RMD?

Do analysts prefer MASI or RMD?

Do institutionals & insiders have more ownership in MASI or RMD?

Does the media favor MASI or RMD?

Summary

How does Masimo compare to DexCom?

Which has higher earnings & valuation, MASI or DXCM?

Is MASI or DXCM more profitable?

Which has more volatility and risk, MASI or DXCM?

Do analysts prefer MASI or DXCM?

Do insiders and institutionals have more ownership in MASI or DXCM?

Does the media favor MASI or DXCM?

Summary

How does Masimo compare to STERIS?

Does the media favor MASI or STE?

Do analysts prefer MASI or STE?

Do insiders and institutionals have more ownership in MASI or STE?

Which has higher earnings & valuation, MASI or STE?

Which has more volatility and risk, MASI or STE?

Is MASI or STE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools